MicroAlgo Inc. (the "Company" or "MicroAlgo") (NASDAQ: MLGO), today announced that they have developed a set of quantum algorithms for feedforward neural networks, breaking through the performance ...
The FDA has approved Otarmeni, the first-ever gene therapy for genetic hearing loss caused by the OTOF gene, for both ...
The U.S. Food and Drug Administration today approved Otarmeni (lunsotogene parvec-cwha), the first-ever dual adeno-associated virus (AAV) vector-based gene therapy. Otarmeni is indicated for the ...
First FDA-approved gene therapy for hearing loss targets a rare inherited form of deafness Treatment restored hearing in most ...
Approval in severe-to-profound and profound OTOF-related hearing loss is based on pivotal results of the CHORD trial demonstrating 80% of participants achieved or surpassed a hearing level meeting the ...
Morning Overview on MSN
FDA approves Regeneron’s first gene therapy for inherited deafness in children
When the parents of a toddler born profoundly deaf learned their child carried mutations in both copies of the OTOF gene, a ...
A model for the structure of the electron is proposed, in which the electron is composed of electric tripole, i.e., a +1 ...
The U.S. Food and Drug Administration has approved Otarmeni, the first gene therapy for genetic hearing loss, targeting OTOF gene mutations that cause severe-to-profound deafness. The one-time ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results